Syneos Health, Inc. provides biopharmaceutical outsourcing solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America.
Syneos Health Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$95.28|
|52 Week High||US$50.27|
|52 Week Low||US$97.48|
|1 Month Change||7.84%|
|3 Month Change||10.39%|
|1 Year Change||83.57%|
|3 Year Change||91.13%|
|5 Year Change||113.63%|
|Change since IPO||365.01%|
Recent News & Updates
When Should You Buy Syneos Health, Inc. (NASDAQ:SYNH)?
While Syneos Health, Inc. ( NASDAQ:SYNH ) might not be the most widely known stock at the moment, it saw a decent share...
Syneos Health (NASDAQ:SYNH) Has A Pretty Healthy Balance Sheet
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Calculating The Intrinsic Value Of Syneos Health, Inc. (NASDAQ:SYNH)
How far off is Syneos Health, Inc. ( NASDAQ:SYNH ) from its intrinsic value? Using the most recent financial data...
|SYNH||US Life Sciences||US Market|
Return vs Industry: SYNH exceeded the US Life Sciences industry which returned 54.2% over the past year.
Return vs Market: SYNH exceeded the US Market which returned 31.5% over the past year.
Stable Share Price: SYNH is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 2% a week.
Volatility Over Time: SYNH's weekly volatility (2%) has been stable over the past year.
About the Company
Syneos Health, Inc. provides biopharmaceutical outsourcing solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers various services spanning Phases I to IV of clinical development, including full service global studies, as well as individual service offerings, such as clinical monitoring, investigator recruitment, patient recruitment, data management, and study startup to assist customers with their drug development process.
Syneos Health Fundamentals Summary
|SYNH fundamental statistics|
Is SYNH overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|SYNH income statement (TTM)|
|Cost of Revenue||US$3.61b|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||2.27|
|Net Profit Margin||4.99%|
How did SYNH perform over the long term?See historical performance and comparison
Is Syneos Health undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: SYNH ($95.28) is trading below our estimate of fair value ($108.08)
Significantly Below Fair Value: SYNH is trading below fair value, but not by a significant amount.
Price To Earnings Ratio
PE vs Industry: SYNH is good value based on its PE Ratio (41.8x) compared to the US Life Sciences industry average (51.2x).
PE vs Market: SYNH is poor value based on its PE Ratio (41.8x) compared to the US market (17.5x).
Price to Earnings Growth Ratio
PEG Ratio: SYNH is poor value based on its PEG Ratio (2x)
Price to Book Ratio
PB vs Industry: SYNH is good value based on its PB Ratio (3x) compared to the US Life Sciences industry average (6.1x).
How is Syneos Health forecast to perform in the next 1 to 3 years based on estimates from 9 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SYNH's forecast earnings growth (20.9% per year) is above the savings rate (2%).
Earnings vs Market: SYNH's earnings (20.9% per year) are forecast to grow faster than the US market (14.9% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: SYNH's revenue (7.8% per year) is forecast to grow slower than the US market (9.8% per year).
High Growth Revenue: SYNH's revenue (7.8% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: SYNH's Return on Equity is forecast to be low in 3 years time (15%).
How has Syneos Health performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: SYNH has high quality earnings.
Growing Profit Margin: SYNH's current net profit margins (5%) are higher than last year (4.1%).
Past Earnings Growth Analysis
Earnings Trend: SYNH's earnings have grown significantly by 31.1% per year over the past 5 years.
Accelerating Growth: SYNH's earnings growth over the past year (25.9%) is below its 5-year average (31.1% per year).
Earnings vs Industry: SYNH earnings growth over the past year (25.9%) underperformed the Life Sciences industry 56.9%.
Return on Equity
High ROE: SYNH's Return on Equity (7.3%) is considered low.
How is Syneos Health's financial position?
Financial Position Analysis
Short Term Liabilities: SYNH's short term assets ($1.7B) exceed its short term liabilities ($1.6B).
Long Term Liabilities: SYNH's short term assets ($1.7B) do not cover its long term liabilities ($3.2B).
Debt to Equity History and Analysis
Debt Level: SYNH's debt to equity ratio (88.7%) is considered high.
Reducing Debt: SYNH's debt to equity ratio has reduced from 157.2% to 88.7% over the past 5 years.
Debt Coverage: SYNH's debt is not well covered by operating cash flow (16.9%).
Interest Coverage: SYNH's interest payments on its debt are well covered by EBIT (4.6x coverage).
What is Syneos Health current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate SYNH's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate SYNH's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if SYNH's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if SYNH's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of SYNH's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Alistair Macdonald (51 yo)
Mr. Alistair Macdonald has been the Chief Executive Officer and Director of Syneos Health, Inc. (formerly, INC Research Holdings, Inc.) since October 1, 2016. Mr. Macdonald served as the Chief Operating Of...
CEO Compensation Analysis
Compensation vs Market: Alistair's total compensation ($USD7.78M) is below average for companies of similar size in the US market ($USD11.42M).
Compensation vs Earnings: Alistair's compensation has been consistent with company performance over the past year.
Experienced Management: SYNH's management team is considered experienced (3.4 years average tenure).
Experienced Board: SYNH's board of directors are considered experienced (4.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Syneos Health, Inc.'s employee growth, exchange listings and data sources
- Name: Syneos Health, Inc.
- Ticker: SYNH
- Exchange: NasdaqGS
- Founded: 2010
- Industry: Life Sciences Tools and Services
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$9.860b
- Shares outstanding: 103.48m
- Website: https://www.syneoshealth.com
Number of Employees
- Syneos Health, Inc.
- 1030 Sync Street
- North Carolina
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/09/22 22:44|
|End of Day Share Price||2021/09/22 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.